What were the key takeaways from Genmab’s earnings call?

What is the revenue and EPS growth rate for Genmab year over year?

What guidance did Genmab's management provide for the next earnings period?

Did Genmab beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Genmab next quarter?

What is Genmab's gross profit margin?

What does Genmab do and what are its main business segments?

What is Genmab's latest dividend and current dividend yield?

- **Revenue Growth**: 19% YoY to $3.7 billion, with proprietary medicines contributing 28% of total revenue.
- **Pipeline Catalysts**: Up to 6 registrational readouts in 2026 for EPKINLY, Rina-S, and petosemtamab.
- **Commercial Momentum**: EPKINLY sales up 17% to $468 million; TIVDAK expands into Europe with $164 million in sales.
- **Strategic Investments**: $1.15 billion operating profit in 2026 to fund late-stage development and launches.
- **Pipeline Expansion**: 3 IND filings for next-gen ADCs and bispecifics; Merus integration accelerates head and neck cancer trials.

**【CEO Summary Section】**
- Total revenue grew 19% in 2025, driven by royalty portfolio and proprietary medicines sales.
- Key milestones include FDA approval of EPKINLY in second-line follicular lymphoma and acquisition of Merus for petosemtamab.
- 2026 outlook includes up to 6 registrational data readouts for EPKINLY, Rina-S, and petosemtamab.

**【Commercial Performance Summary】**
- EPKINLY sales reached $468 million (17% YoY growth), with strong uptake in the U.S. and Japan.
- TIVDAK sales grew 26% to $164 million, with expansion into Europe and Japan.
- Genmab expanded commercial footprint in Germany, U.K., and France.

**【CFO Financial Commentary】**
- 2025 total revenue: $3.7 billion (19% YoY growth).
- Operating profit: $1.26 billion (31% YoY increase).
- 2026 guidance: 14% revenue growth, $1.15 billion operating profit midpoint.
- Strategic investments in late-stage development and launch readiness.

**【Q&A Highlights】**
- **EPKINLY Regulatory Path**: Monotherapy Phase III data confounded by COVID-19 and emerging therapies; combination trials in second-line DLBCL expected to read out in 2026.
- **Rina-S Potential**: Phase II data in platinum-resistant ovarian cancer could support accelerated approval; Phase III trials in endometrial and PSOC cancers ongoing.
- **Petosemtamab Expansion**: First-line head and neck cancer Phase III trials anticipated; colorectal cancer data maturing.
- **Pipeline Investment**: Genmab prioritizes next-gen ADCs and bispecifics, with 3 IND filings in late 2025.
- **Debt Strategy**: $5.5 billion debt offering to support growth, targeting <3x gross leverage by end-2027.

Genmab A/S (GMAB) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: 21% YoY total revenue, 26% recurring revenue growth, EPKINLY up 64%, TIVDAK launched in Germany.
- **Pipeline Momentum**: Rina-S Phase III in endometrial cancer (50% ORR), EPKINLY awaiting U.S. approval, Merus acquisition adds petosemtamab (2027 launch).
- **Financial Strength**: Operating profit +52%, $3.4B cash, 2026 EBIT significant, 2027 EBITDA growth.

**CEO Summary Section**
- **Revenue Growth**: Total revenue up 21% year-over-year, driven by recurring revenue (96% of total) and strong performance of EPKINLY and TIVDAK. EPKINLY sales grew 64% YoY, while TIVDAK launched in Germany and achieved early success.
- **Pipeline Progress**: Rina-S (folate receptor alpha ADC) showed durable responses in endometrial cancer (50% ORR) and initiated Phase III trials. EPKINLY (CD3/CD19 bispecific) awaits U.S. approval for second-line follicular lymphoma and is on track for a 2027 launch in head and neck cancer. Proposed Merus acquisition adds petosemtamab (EGFR bispecific) with potential 2027 launch.
- **Strategic Moves**: Terminated GEN1042 in first-line head and neck cancer due to insufficient data. Focused on high-impact programs like Rina-S and EPKINLY, with disciplined capital allocation.

**CFO Financial Commentary**
- **Financial Results**: GAAP net income $932M (15% YoY growth), operating profit up 52% to $1.1B. Recurring revenue (royalties, product sales) grew 26%, outpacing one-time revenue. Cash balance $3.4B, supporting strategic investments.
- **Cost Management**: Operating expenses up 7% YoY, driven by pipeline expansion. Maintained strong profitability with 18.9% effective tax rate.

**Q&A Highlights**
- **Competitive Positioning**: Peto (EGFR bispecific) is best-in-class with Phase III trials in head and neck cancer. Rina-S outperforms competitors in endometrial cancer with 50% ORR vs. 15% standard of care. SubQ administration for EPKINLY enhances convenience.
- **Pipeline Updates**: EPKINLY Phase III in frontline DLBCL fully accrued; readout expected 2026. Rina-S Phase III in endometrial cancer on track for 2027 launch. GEN1042 terminated in head and neck but continues in melanoma.
- **Financial Outlook**: 2026 EBIT expected to be significant; 2027 EBITDA growth driven by proprietary portfolio. Merus acquisition to double owned assets, with synergies reducing OpEx.

Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript

- **Revenue Growth Accelerates**: 19% total revenue growth (H1 2025) driven by EPKINLY and Tivdak, with updated 2025 guidance of $3.5–$3.7 billion.
- **Pipeline Breakthroughs**: EPKINLY Phase III data shows 79% PFS improvement; Rina-S achieves 50% ORR in endometrial cancer, with 3 Phase III trials planned.
- **Strategic Focus**: Discontinued HexaBody-OX40 to prioritize high-impact programs, maintaining 26% YoY operating profit growth.
- **Commercial Dominance**: EPKINLY approved in 60+ countries; Tivdak launched in Japan, driving 30% YoY sales growth.
- **Financial Strength**: $3 billion cash balance, 97% recurring revenue, and disciplined capital allocation for long-term growth.

**【Management Opening Remarks】**
- Total revenue grew 19% YoY, driven by recurring revenue and product sales of EPKINLY and Tivdak, which contributed 31% of total revenue growth.
- Operating profit increased 56% YoY to $531 million, supported by strong cost control and disciplined capital allocation.
- Completed a share buyback program, reinforcing confidence in long-term value creation.
- Cash balance of $3 billion provides flexibility for growth and expansion.

**【CEO Commentary】**
- Epcoritamab (EPKINLY) Phase III EPCORE-FL1 trial met dual endpoints with 79% risk reduction in progression-free survival (PFS) and 50% overall response rate (ORR), enabling global regulatory submissions.
- Rina-S (folate receptor-targeted antibody) showed 50% ORR in endometrial cancer and plans for 3 Phase III trials by year-end, targeting 2027 launch in ovarian cancer.
- Acasunlimab Phase II melanoma trial underway, with additional data expected in H2 2025.
- EPKINLY now approved in 60+ countries, uniquely positioned as the only off-the-shelf bispecific for DLBCL and FL.

**【CFO Financial Commentary】**
- 2025 revenue guidance updated to $3.5–$3.7 billion (15% growth midpoint), driven by DARZALEX royalties ($1 billion+) and EPKINLY sales growth.
- Operating expenses (OpEx) projected at $2.1–$2.2 billion, with 6% YoY increase in H1 2025, excluding ProFound Bio acquisition.
- Net profit of $531 million in H1, with 26% YoY growth expected in operating profit.
- Recurring revenue now 97% of total, up from 90% in 2024, reflecting strong pipeline monetization.

**【Q&A Highlights】**
- **Regulatory Strategy**: FDA accepted sBLA for EPKINLY in second-line FL with PDUFA date of November 30, 2025. Global submissions for EPCORE-FL1 data expected soon.
- **Competitive Position**: EPKINLY leads with broad Phase III program and 60+ country approvals; Rina-S shows potential in non-small cell lung cancer with Phase II trial starting Q4 2025.
- **Pipeline Prioritization**: Discontinued HexaBody-OX40 due to lack of differentiation, reallocating resources to high-impact Phase III programs.
- **Commercial Momentum**: EPKINLY sales up 74% YoY to $211 million; Tivdak sales $78 million, up 30% YoY, with Japan launch underway.
- **Risk Management**: Monitoring geopolitical risks but no material impact expected on 2025 guidance.

Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

- **19% Revenue Growth**: Driven by EPKINLY (+73%) and TIVDAK (+22%), with 95% of revenue from recurring sources.
- **$3B+ Cash**: Supports share buyback and strategic investments in late-stage pipeline (epcoritamab, Rina-S, acasunlimab).
- **Rina-S Potential**: $2B peak sales across ovarian and endometrial cancers, with ASCO data expected to reinforce best-in-class profile.
- **EPKINLY Expansion**: Second-line FL submission planned for H1 2025, targeting underserved lymphoma patients.
- **Operational Excellence**: 62% operating profit growth, disciplined cost control, and 12%+ revenue guidance for 2025.

**【CEO Summary Section】**
- Total revenue grew 19% YoY, driven by EPKINLY and TIVDAK sales, with recurring revenue up 33%.
- Emphasized investment in late-stage pipeline (epcoritamab, Rina-S, acasunlimab) and commercialization capabilities.
- Operating profit increased 62% to $195M, with $3B+ cash on hand for strategic flexibility.
- Launched share buyback program of up to 2.2M shares, reflecting confidence in long-term growth.

**【CFO Financial Commentary】**
- GAAP net income: $195M (vs. $121M prior year), driven by strong recurring revenue (95% of total revenue).
- Non-GAAP EPS: $1.08 (vs. $0.85 prior year), exceeding expectations.
- Operating expenses: $485M (+5% YoY), disciplined allocation to high-impact programs.
- 2025 guidance: Revenue $3.3B-$3.7B (12% growth), operating profit $895M-$1.4B.

**【Q&A Key Highlights】**
- **Rina-S Endometrial Cancer Data**: ASCO presentation expected to show compelling efficacy, with potential for $2B peak sales across ovarian and endometrial indications.
- **EPKINLY Second-Line FL Submission**: Planned FDA application in H1 2025, targeting 9,000+ patients with relapsed follicular lymphoma.
- **Commercial Momentum**: EPKINLY sales +73% YoY ($90M Q1), TIVDAK +22% YoY ($33M), expanding into Japan and EU markets.
- **Pipeline Expansion**: Actively pursuing inorganic opportunities in immunology and oncology, leveraging strong financial foundation to acquire late-stage assets.

Genmab A/S (GMAB) Q1 2025 Earnings Conference Call Transcript

- **31% Revenue Growth**: 2024 highlighted by EPKINLY ($281M) and TIVDAK ($131M) launches, with DARZALEX royalties at $11.7B. 
- **Pipeline Momentum**: 3 EPKINLY Phase III readouts by end-2026, Rina-S ovarian/endometrial Phase III starts in 2025. 
- **Financial Strength**: $3B cash balance, 2025 operating profit guidance of $1.1B (+16%). 
- **Strategic Focus**: 55% R&D to late-stage assets, $370M buyback announced despite HexaBody uncertainty. 
- **Peak Sales Potential**: EPKINLY >$3B, Rina-S >$2B, Acasunlimab $1B. 


**【CEO Opening Remarks】**
- 2024 revenue grew 31% to $2.8B, driven by EPKINLY ($281M) and TIVDAK ($131M) launches, alongside strong DARZALEX royalties ($11.7B). 
- $1.8B acquisition of ProfoundBio and $500M share buyback executed while maintaining $3B cash balance.
- 2025 focus on advancing EPKINLY (3 Phase III readouts by end-2026), Rina-S (2 Phase III trials), and Acasunlimab (solid tumor expansion). 

**【CFO Financial Highlights】**
- 2024 operating profit up 26% to DKK7.8B ($1.1B), with 91% of revenue recurring (vs 88% in 2023). 
- 2025 guidance: $3.3-3.7B revenue (+12% midpoint), $895M-$1.4B operating profit (+16% midpoint). 
- EPKINLY/TIVDAK to contribute 34% of 2025 revenue growth. 
- R&D allocation: 55% to late-stage assets (vs 45% in 2024). 

**【Pipeline Updates】**
- **EPKINLY**: 
  - 3 Phase III trials fully recruited (DLBCL frontline, FL 2L+, DLBCL 2L+ transplant-ineligible). 
  - 3-year CR durability data at ASH shows 50% CRs maintained. 
  - Japan FL indication approval expected Q1 2025. 
- **Rina-S**: 
  - Ovarian cancer Phase III (PROC) and endometrial cancer Phase III starts in 2025. 
  - Potential peak sales >$2B targeting 85% of platinum-resistant ovarian patients. 
- **Acasunlimab**: 
  - Full Genmab control post-ProfoundBio acquisition. 
  - 2L+ NSCLC Phase II data expected 2025. 
  - Peak sales potential $1B for 136K treatable PD-L1+ patients. 

**【Commercial Execution】**
- EPKINLY: 
  - US/JP sales growth driven by FL launch (June 2024). 
  - 2025 Phase III trials in frontline DLBCL and FL 2L+. 
- TIVDAK: 
  - Europe launch expected 2025 post-CHMP positive opinion. 
  - Genmab taking full commercial control outside US/China. 
  - Japan approval pending Q1 2025. 

**【Q&A Key Takeaways】**
- **Rina-S Endometrial Cancer**: Phase III start in 2025 after strong PROC expansion data. 
- **EPKINLY Frontline DLBCL**: Phase III fully recruited, PFS readout 2026. 
- **Capital Allocation**: 2025 buyback of $370M announced despite pending HexaBody decision. 
- **BD Strategy**: Seeking Phase III-ready antibody-based assets to complement internal pipeline. 


Actual				0.0622	0.8141	0.1264	0.1427	0.2694	0.0732	0.2086	0.1654	0.0987	0.3986	0.5281	0.1248	0.0503	0.3049	0.464	0.1395	0.2916	0.3172	0.2872	0.851	0.305	0.542	0.646	0.4715
Forecast				0.0186	0.8141	0.0955	0.1229	0.046	0.0723	0.1315	0.1494	0.0792	0.1942	0.2195	0.3378	0.0937	0.2898	0.3292	0.3134	0.1861	0.3113	0.3084	0.3741	0.2349	0.3993	0.4861	0.4438
Surprise	0.00%	0.00%	0.00%	+234.41%	0.00%	+32.36%	+16.11%	+485.65%	+1.24%	+58.63%	+10.71%	+24.62%	+105.25%	+140.59%	-63.06%	-46.32%	+5.21%	+40.95%	-55.49%	+56.69%	+1.90%	-6.87%	+127.48%	+29.84%	+35.74%	+32.89%	+6.24%

GMAB

GMAB fundamentals

GMAB Q4 2025 Earnings

Earnings Call

You can ask Aime

GMAB

GMAB fundamentals

GMAB Q4 2025 Earnings

Earnings Call

GMAB Earnings Call Summary for Q4/202512:00 PM on Feb 17, 2026

GMAB Earnings Call Summary for Q3/202512:00 PM on Nov 6, 2025

GMAB Earnings Call Summary for Q2/202512:00 PM on Aug 7, 2025

GMAB Earnings Call Summary for Q1/202512:00 PM on May 8, 2025

GMAB Earnings Call Summary for Q4/202412:00 PM on Feb 12, 2025

You can ask Aime